Vanguard Group
UTMD icon

Vanguard Group’s Utah Medical Products UTMD Stock Holding History

Vanguard Group’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$9.85M Buy
175,971
+344
+0.2% +$19.9K ﹤0.01% 2974
2025
Q3 		$11.1M Sell
175,627
-1,470
-0.8% -$87K ﹤0.01% 2931
2025
Q2 		$10.1M Buy
177,097
+730
+0.4% +$39.7K ﹤0.01% 2895
2025
Q1 		$9.88M Sell
176,367
-801
-0.5% -$48K ﹤0.01% 2851
2024
Q4 		$10.9M Sell
177,168
-4,001
-2% -$259K ﹤0.01% 2906
2024
Q3 		$12.1M Buy
181,169
+2,594
+1% +$176K ﹤0.01% 2860
2024
Q2 		$11.9M Sell
178,575
-4,566
-2% -$311K ﹤0.01% 2816
2024
Q1 		$13M Buy
183,141
+12,402
+7% +$930K ﹤0.01% 2817
2023
Q4 		$14.4M Buy
170,739
+2,581
+2% +$214K ﹤0.01% 2754
2023
Q3 		$14.5M Buy
168,158
+610
+0.4% +$56.3K ﹤0.01% 2684
2023
Q2 		$15.6M Sell
167,548
-1,387
-0.8% -$131K ﹤0.01% 2698
2023
Q1 		$16M Buy
168,935
+1,245
+0.7% +$114K ﹤0.01% 2685
2022
Q4 		$16.9M Buy
167,690
+872
+0.5% +$79.6K ﹤0.01% 2710
2022
Q3 		$14.2M Sell
166,818
-484
-0.3% -$42.7K ﹤0.01% 2782
2022
Q2 		$14.4M Buy
167,302
+1,403
+0.8% +$120K ﹤0.01% 2805
2022
Q1 		$14.9M Sell
165,899
-23,674
-12% -$2.18M ﹤0.01% 2935
2021
Q4 		$19M Sell
189,573
-26,120
-12% -$2.67M ﹤0.01% 2866
2021
Q3 		$20M Buy
215,693
+21,419
+11% +$1.89M ﹤0.01% 2861
2021
Q2 		$16.5M Sell
194,274
-1,137
-0.6% -$98.4K ﹤0.01% 2931
2021
Q1 		$16.9M Buy
195,411
+6,474
+3% +$569K ﹤0.01% 2867
2020
Q4 		$15.9M Buy
188,937
+14,905
+9% +$1.27M ﹤0.01% 2752
2020
Q3 		$13.9M Buy
174,032
+523
+0.3% +$43.4K ﹤0.01% 2626
2020
Q2 		$15.4M Sell
173,509
-5
-0% -$449 ﹤0.01% 2552
2020
Q1 		$16.3M Sell
173,514
-1,119
-0.6% -$104K ﹤0.01% 2381
2019
Q4 		$18.8M Sell
174,633
-15,123
-8% -$1.53M ﹤0.01% 2562
2019
Q3 		$18.2M Buy
189,756
+2,174
+1% +$202K ﹤0.01% 2533
2019
Q2 		$18M Buy
187,582
+806
+0.4% +$67.9K ﹤0.01% 2565
2019
Q1 		$16.5M Buy
186,776
+6,331
+4% +$557K ﹤0.01% 2593
2018
Q4 		$15M Buy
180,445
+578
+0.3% +$50.9K ﹤0.01% 2578
2018
Q3 		$16.9M Buy
179,867
+27,623
+18% +$2.64M ﹤0.01% 2657
2018
Q2 		$16.8M Buy
152,244
+25,045
+20% +$2.62M ﹤0.01% 2644
2018
Q1 		$12.6M Sell
127,199
-35,271
-22% -$3.15M ﹤0.01% 2710
2017
Q4 		$13.2M Buy
162,470
+10,695
+7% +$835K ﹤0.01% 2695
2017
Q3 		$11.2M Buy
151,775
+19,847
+15% +$1.43M ﹤0.01% 2757
2017
Q2 		$9.55M Sell
131,928
-411
-0.3% -$27.1K ﹤0.01% 2795
2017
Q1 		$8.24M Sell
132,339
-3,037
-2% -$191K ﹤0.01% 2845
2016
Q4 		$9.85M Buy
135,376
+1,947
+1% +$127K ﹤0.01% 2753
2016
Q3 		$7.98M Sell
133,429
-7,757
-5% -$493K ﹤0.01% 2797
2016
Q2 		$8.89M Buy
141,186
+3,275
+2% +$211K ﹤0.01% 2706
2016
Q1 		$8.63M Buy
137,911
+41,761
+43% +$2.46M ﹤0.01% 2688
2015
Q4 		$5.63M Buy
96,150
+9,899
+11% +$561K ﹤0.01% 2934
2015
Q3 		$4.65M Buy
86,251
+5,023
+6% +$274K ﹤0.01% 3001
2015
Q2 		$4.84M Buy
81,228
+900
+1% +$50.7K ﹤0.01% 3032
2015
Q1 		$4.81M Buy
80,328
+2,667
+3% +$157K ﹤0.01% 3014
2014
Q4 		$4.66M Buy
77,661
+244
+0.3% +$13.5K ﹤0.01% 2935
2014
Q3 		$3.77M Buy
77,417
+1,800
+2% +$91.4K ﹤0.01% 2984
2014
Q2 		$3.89M Sell
75,617
-1,801
-2% -$92.5K ﹤0.01% 2975
2014
Q1 		$4.48M Buy
77,418
+1,266
+2% +$69.1K ﹤0.01% 2883
2013
Q4 		$4.35M Buy
76,152
+7,825
+11% +$429K ﹤0.01% 2871
2013
Q3 		$4.06M Buy
68,327
+3,254
+5% +$178K ﹤0.01% 2845
2013
Q2 		$3.53M Buy
+65,073
New +$3.06M ﹤0.01% 2855

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group's UTMD Position: Q4 2025 in Review

Vanguard Group increased its Utah Medical Products (UTMD) stake by 0.2% in Q4 2025, buying an estimated $19.9K and bringing the position to 175,971 shares worth $9.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2974.

Vanguard Group first reported a position in UTMD in Q2 2013 and has held it in 51 quarters since. The position peaked at $20M in Q3 2021. 117 funds tracked by Wall St. Rank hold UTMD as of Q4 2025.

  • Vanguard Group held 175,971 shares of Utah Medical Products worth $9.85M as of Q4 2025.
  • Vanguard Group bought 344 Utah Medical Products shares in Q4 2025, an estimated $19.9K.
  • Utah Medical Products made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2974 holding.
  • Vanguard Group first reported a position in Utah Medical Products in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's Utah Medical Products position peaked at $20M in Q3 2021.
  • 117 funds tracked by Wall St. Rank held Utah Medical Products as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.